Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI188 + Azacitidine in Higher Risk MDS
NCT04511975Phase 1Suspended
- Sponsor
- Innovent Biologics
- Start
- Aug 2020
- Primary completion
- Oct 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of letaplimab in myelodysplastic syndrome (MDS), sponsored by Innovent Biologics. Primary endpoints: Adverse Events at 28 days and Efficacy of IBI188 in combination with AZA at 28 days. Started Aug 2020; status: suspended.
02
Drugs
letaplimab
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04511975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04511975.